Accumulating data indicate that the exposure of PCa to different anticancer compounds, ionizing radiation, and selected AR ligands induce a senescent phenotype, which is referred to as therapy-induced cell senescence (TIS). The gene discussed is AR; the disease is posterior cortical atrophy.